

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	5
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL CENTRAL NERVOUS SYSTEM</i>	
<i>FORECAST BY DISEASE CLASS, THROUGH 2015 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL CENTRAL NERVOUS SYSTEM</i>	
<i>FORECAST BY DISEASE CLASS, 2008-2015 (\$ MILLIONS)</i>	7
EXECUTIVE SUMMARY (CONTINUED).....	8
 CHAPTER THREE: OVERVIEW	 9
CURRENT STATE OF CENTRAL NERVOUS SYSTEM DISEASE	9
ESTABLISHED DRUG SEGMENTS	10
PSYCHIATRY	10
DEPRESSION	10
MULTIPLE SCLEROSIS / PARKINSON'S	10
EPILEPSY/CONVULSION.....	11
ALZHEIMER'S	11
ATTENTION DEFICIT HYPERACTIVITY	
DISORDER/NARCOLEPSY	11
MIGRAINE	11
OTHER	12
KEY RECENT EVENTS IN THE CENTRAL NERVOUS SYSTEM	
MARKET.....	12
2009 FDA PEDIATRIC ADVISORY COMMITTEE ON	
PRESCRIPTION OF ANTIPSYCHOTICS	12
GROWTH SEEN VIA PURSUIT OF ADDITIONAL	
INDICATIONS VERSUS NCE APPROVALS	13
ALZHEIMER'S DRUGS IN JAPAN OPEN UP LARGE	
OPPORTUNITIES, DRIVEN BY DEMOGRAPHICS	13
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT.....	13
<i>TABLE 1 RECENTLY APPROVED AND PIPELINE FORECAST, 2009-</i>	
<i>2015 (\$ MILLIONS)</i>	14
 CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE	
ANALYSIS.....	15
INDUSTRY STRUCTURE	15

<i>TABLE 2 CENTRAL NERVOUS SYSTEM MARKET SEGMENTS: SIZE, GROWTH, SHARE (\$ MILLIONS)</i>	16
MARKET CONCENTRATION AND PRICE SENSITIVITY	17
<i>TABLE 3 COMPANY BY DISEASE CLASS, 2010 REVENUE (\$ MILLIONS)</i>	18
<i>TABLE 3 (CONTINUED)</i>	19
MARKET TRENDS	19
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume	19
Significant Impact of Patient Advocacy Groups in CNS Disease.....	20
Growth Seen via Pursuit of Additional Indications versus NCE Approvals.....	20
Improving Performance in Depression Treatments.....	20
Alzheimer’s Therapy Continues to Receive Large and Important Investment.....	20
<i>TABLE 4 PATENT EXPIRATION OF CENTRAL NERVOUS SYSTEM DRUGS, 2010 AND 2015 (\$ MILLIONS)</i>	21
<i>TABLE 5 COMPANY BY DISEASE CLASS, 2015 REVENUE (\$ MILLIONS)</i>	22
<i>TABLE 6 MARKET SHARE BY LEADING CENTRAL NERVOUS SYSTEM PLAYERS, 2010 (\$ MILLIONS/%)</i>	23
<i>TABLE 7 LARGEST REVENUE GENERATING THERAPIES IN THE CENTRAL NERVOUS SYSTEM DISEASE (\$ MILLIONS)</i>	24
CHAPTER FIVE: MARKETS BY DISEASE	25
SUMMARY OF MARKET DYNAMICS	25
<i>TABLE 8 GLOBAL CENTRAL NERVOUS SYSTEM FORECAST BY DISEASE CLASS THROUGH 2015 (\$ MILLIONS)</i>	26
PSYCHIATRY	26
MARKET DYNAMICS	26
TREATMENT AND MANAGEMENT.....	27
<i>TABLE 9 CURRENT GLOBAL PSYCHIATRY MARKET, THROUGH 2010 (\$ MILLIONS)</i>	27
<i>TABLE 9 (CONTINUED)</i>	28
Seroquel	28
Zyprexa.....	29
Abilify	29
Geodon/Zeldox.....	30
Risperdal	31
<i>TABLE 10 GLOBAL PSYCHIATRY MARKET, THROUGH 2015 (\$ MILLIONS)</i>	32
<i>TABLE 11 FORECAST EPIDEMIOLOGY: PSYCHIATRY</i>	32
DEPRESSION.....	33
MARKET DYNAMICS	33

TREATMENT AND MANAGEMENT.....	33
<i>TABLE 12 CURRENT GLOBAL DEPRESSION MARKET, THROUGH 2010 (\$ MILLIONS)</i>	33
Lexapro	34
Effexor	34
Cymbalta.....	35
GENERIC DRUG TRENDS: DEPRESSION	35
<i>TABLE 13 GLOBAL DEPRESSION MARKET, THROUGH 2015 (\$ MILLIONS)</i>	36
<i>TABLE 14 FORECAST EPIDEMIOLOGY: DEPRESSION</i>	36
MULTIPLE SCLEROSIS AND PARKINSON'S.....	36
MARKET DYNAMICS	36
<i>TABLE 15 CURRENT GLOBAL MS AND PARKINSON'S MARKET, THROUGH 2010 (\$ MILLIONS)</i>	37
TREATMENT AND MANAGEMENT.....	37
Requip	37
GENERIC DRUG TRENDS: PARKINSON'S	38
<i>TABLE 16 GLOBAL MS AND PARKINSON'S MARKET, THROUGH 2015 (\$ MILLIONS)</i>	38
<i>TABLE 17 FORECAST EPIDEMIOLOGY: MS/PARKINSONS, THROUGH 2015</i>	39
EPILEPSY/CONVULSIONS	39
MARKET DYNAMICS	39
<i>TABLE 18 CURRENT GLOBAL EPILEPSY MARKET, THROUGH 2010 (\$ MILLIONS)</i>	39
<i>TABLE 18 (CONTINUED)</i>	40
TREATMENT AND MANAGEMENT.....	40
Topamax.....	40
Lyrica	40
Lamictal	41
GENERIC DRUG TRENDS: EPILEPSY/CONVULSIONS	41
<i>TABLE 19 GLOBAL EPILEPSY MARKET, THROUGH 2015 (\$ MILLIONS)</i>	42
ALZHEIMER'S.....	42
MARKET DYNAMICS	42
<i>TABLE 20 CURRENT GLOBAL ALZHEIMER'S MARKET, THROUGH 2010 (\$ MILLIONS)</i>	43
TREATMENT AND MANAGEMENT.....	44
Aricept.....	44
Exelon.....	44
Namenda.....	45
<i>TABLE 21 GLOBAL ALZHEIMER'S MARKET, THROUGH 2015 (\$ MILLIONS)</i>	45
<i>TABLE 21 (CONTINUED)</i>	46

GENERIC DRUG TRENDS: ALZHEIMER'S	46
ADHD AND NARCOLEPSY	46
MARKET DYNAMICS	46
TABLE 22 CURRENT GLOBAL ADHD / NARCOLEPSY MARKET, THROUGH 2010 (\$ MILLIONS).....	47
TREATMENT AND MANAGEMENT.....	47
Concerta	47
Provigil	48
Vyvanse	48
Adderall.....	49
Strattera.....	49
TABLE 23 GLOBAL ADHD/NARCOLEPSY MARKET, THROUGH 2015 (\$ MILLIONS).....	50
GENERIC DRUG TRENDS: ADHD/NARCOLEPSY	50
MIGRAINE AND OTHER CNS DISEASE	50
MARKET DYNAMICS	50
TABLE 24 CURRENT GLOBAL MIGRAINE DISEASE MARKET, THROUGH 2010 (\$ MILLIONS).....	51
TABLE 25 CURRENT GLOBAL OTHER CNS DISEASE MARKET, THROUGH 2010 (\$ MILLIONS).....	51
TABLE 25 (CONTINUED).....	52
TREATMENT AND MANAGEMENT.....	52
Ambien	52
Lunesta	52
TABLE 26 GLOBAL MIGRAINE MARKET, THROUGH 2015 (\$ MILLIONS).....	53
TABLE 27 GLOBAL OTHER CENTRAL NERVOUS SYSTEM MARKET THROUGH 2015 (\$ MILLIONS).....	54
CHAPTER SIX: MARKETS BY GEOGRAPHY	55
SUMMARY.....	55
TABLE 28 CURRENT MARKET SIZE BY GEOGRAPHY, THROUGH 2010 (\$ MILLIONS).....	55
METHODOLOGY.....	55
TABLE 29 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....	56
UNITED STATES.....	56
TABLE 30 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: PSYCHIATRY, THROUGH 2015.....	57
TABLE 31 PEVALENCE OF EPIDEMIOLOGY IN THE U.S.: DEPRESSION, THROUGH 2015.....	57
TABLE 32 PREVALENCE OF EPIDEMIOLOGY IN THE U.S.: STROKE, THROUGH 2015.....	57
WESTERN EUROPE.....	57

<i>TABLE 33 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: PSYCHIATRY, THROUGH 2015</i>	58
<i>TABLE 34 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: DEPRESSION, THROUGH 2015</i>	59
<i>TABLE 35 PREVALENCE OF EPIDEMIOLOGY IN WESTERN EUROPE: STROKE, THROUGH 2015</i>	59
JAPAN.....	59
<i>TABLE 36 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: PSYCHIATRY, THROUGH 2015</i>	60
<i>TABLE 37 PREVALENCE OF EPIDEMIOLOGY IN JAPAN: DEPRESSION, THROUGH 2015</i>	60
EMERGING MARKETS.....	60
STRATEGIES TO ACCESS EMERGING MARKETS.....	60
EMERGING MARKETS FORECAST.....	61
BRAZIL.....	62
Market Overview.....	62
Regulatory Considerations.....	62
Patent Considerations.....	62
<i>TABLE 38 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: PSYCHIATRY, THROUGH 2015</i>	63
<i>TABLE 39 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: DEPRESSION, THROUGH 2015</i>	63
<i>TABLE 40 PREVALENCE OF EPIDEMIOLOGY IN BRAZIL: STROKE, THROUGH 2015</i>	64
CHINA.....	64
Market Overview.....	64
Regulatory Considerations.....	64
Patent Considerations.....	65
<i>TABLE 41 PREVALENCE OF EPIDEMIOLOGY IN CHINA: PSYCHIATRY, THROUGH 2015</i>	66
<i>TABLE 42 PREVALENCE OF EPIDEMIOLOGY IN CHINA: DEPRESSION, THROUGH 2015</i>	66
<i>TABLE 43 PREVALENCE OF EPIDEMIOLOGY IN CHINA: STROKE, THROUGH 2015</i>	66
INDIA.....	67
Market Overview.....	67
Regulatory Considerations.....	67
Patent Considerations.....	67
<i>TABLE 44 PREVALENCE OF EPIDEMIOLOGY IN INDIA: PSYCHIATRY, THROUGH 2015</i>	68
<i>TABLE 45 PREVALENCE OF EPIDEMIOLOGY IN INDIA: DEPRESSION, THROUGH 2015</i>	68
<i>TABLE 46 PREVALENCE OF EPIDEMIOLOGY IN INDIA: STROKE, THROUGH 2015</i>	68

RUSSIA.....	69
Market Overview	69
Regulatory Considerations.....	69
Patent Considerations	69
<i>TABLE 47 PEVALENCE OF EPIDEMIOLOGY IN RUSSIA:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>70</i>
<i>TABLE 48 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>70</i>
<i>TABLE 49 PREVALENCE OF EPIDEMIOLOGY IN RUSSIA: STROKE,</i>	
<i>THROUGH 2015.....</i>	<i>70</i>
SOUTH AMERICA.....	70
<i>TABLE 50 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>71</i>
<i>TABLE 51 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>71</i>
<i>TABLE 52 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AMERICA:</i>	
<i>STROKE, THROUGH 2015.....</i>	<i>71</i>
CARIBBEAN	71
<i>TABLE 53 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>72</i>
<i>TABLE 54 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>72</i>
<i>TABLE 55 PREVALENCE OF EPIDEMIOLOGY IN THE CARIBBEAN:</i>	
<i>STROKE, THROUGH 2015.....</i>	<i>72</i>
NORTHERN EUROPE	73
<i>TABLE 56 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN</i>	
<i>EUROPE: PSYCHIATRY, THROUGH 2015.....</i>	<i>73</i>
<i>TABLE 57 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN</i>	
<i>EUROPE: DEPRESSION, THROUGH 2015.....</i>	<i>73</i>
<i>TABLE 58 PREVALENCE OF EPIDEMIOLOGY IN NORTHERN</i>	
<i>EUROPE: STROKE, THROUGH 2015.....</i>	<i>73</i>
CENTRAL AND EASTERN EUROPE.....	74
<i>TABLE 59 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND</i>	
<i>EASTERN EUROPE: PSYCHIATRY, THROUGH 2015.....</i>	<i>74</i>
<i>TABLE 60 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND</i>	
<i>EASTERN EUROPE: DEPRESSION, THROUGH 2015.....</i>	<i>74</i>
<i>TABLE 61 PREVALENCE OF EPIDEMIOLOGY IN CENTRAL AND</i>	
<i>EASTERN EUROPE:STROKE, THROUGH 2015.....</i>	<i>74</i>
AUSTRALIA.....	75
<i>TABLE 62 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>75</i>
<i>TABLE 63 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>75</i>

<i>TABLE 64 PREVALENCE OF EPIDEMIOLOGY IN AUSTRALIA:</i>	
<i>STROKE, THROUGH 2015.....</i>	<i>75</i>
<i>ASIA–OTHER.....</i>	<i>76</i>
<i>TABLE 65 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>76</i>
<i>TABLE 66 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>76</i>
<i>TABLE 67 PREVALENCE OF EPIDEMIOLOGY IN ASIA - OTHER:</i>	
<i>STROKE, THROUGH 2015.....</i>	<i>76</i>
<i>MIDDLE EAST.....</i>	<i>77</i>
<i>TABLE 68 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE</i>	
<i>EAST: PSYCHIATRY, THROUGH 2015.....</i>	<i>77</i>
<i>TABLE 69 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE</i>	
<i>EAST: DEPRESSION, THROUGH 2015.....</i>	<i>77</i>
<i>TABLE 70 PREVALENCE OF EPIDEMIOLOGY IN THE MIDDLE</i>	
<i>EAST: STROKE, THROUGH 2015.....</i>	<i>77</i>
<i>SOUTHERN AFRICA.....</i>	<i>78</i>
<i>TABLE 71 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA:</i>	
<i>PSYCHIATRY, THROUGH 2015.....</i>	<i>78</i>
<i>TABLE 72 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA:</i>	
<i>DEPRESSION, THROUGH 2015.....</i>	<i>78</i>
<i>TABLE 73 PREVALENCE OF EPIDEMIOLOGY IN SOUTH AFRICA:</i>	
<i>STROKE, THROUGH 2015.....</i>	<i>78</i>
<i>AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY</i>	
<i>FORECAST.....</i>	<i>79</i>
 CHAPTER SEVEN: PIPELINE ANALYSIS.....	 80
<i>TABLE 74 APPROVED PRODUCT FORECAST, 2009-2015 (\$</i>	
<i>MILLIONS).....</i>	<i>80</i>
<i>MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT.....</i>	<i>80</i>
<i>KEY TRENDS IN RESEARCH AND DEVELOPMENT.....</i>	<i>80</i>
<i>SNRIs Improve the Baseline Performance of Leading</i>	
<i>Depression Therapies.....</i>	<i>80</i>
<i>New Products Provide Larger Opportunities Compared to</i>	
<i>Product Extensions.....</i>	<i>81</i>
<i>Combination Products Yield Greater Therapeutic</i>	
<i>Response.....</i>	<i>81</i>
<i>Alzheimer’s Therapy Continues to Receive Large and</i>	
<i>Important Investment.....</i>	<i>82</i>
<i>KEY PRODUCTS UNDER MAJOR CNS DISORDERS.....</i>	<i>82</i>
<i>Schizophrenia.....</i>	<i>82</i>
<i>Depression.....</i>	<i>83</i>
<i>Alzheimer’s.....</i>	<i>83</i>
<i>Parkinson’s Disease.....</i>	<i>84</i>
<i>Epilepsy.....</i>	<i>84</i>

Insomnia	84
Attention Deficit Hyperactivity Disorder	85
Other Indications.....	85
2009 APPROVALS IN CENTRAL NERVOUS SYSTEM THERAPY.....	85
PHASE III AND PENDING APPROVAL COMPOUNDS.....	85
Bapineuzumab (AAB-001)—Elan/Wyeth/Pfizer	85
TABLE 75 <i>BAPINEUZUMAB (AAB-001)—ELAN/WYETH/PFIZER</i>	85
Bapineuzumab (Continued).....	86
Telcagepant (MK-0974)—Merck	87
TABLE 76 <i>TELCAGEPANT (MK-0974)—MERCCK</i>	87
Telcagepant ... (Continued).....	88
Solanezumab (LY2062430)—Eli Lilly.....	89
TABLE 77 <i>SOLANEZUMAB (LY2062430)—ELI LILLY</i>	89
Semagacestat (LY450139)—Eli Lilly	90
TABLE 78 <i>SEMAGACESTAT (LY450139)—ELI LILLY</i>	90
Vilazodone—Clinical Data	91
TABLE 79 <i>VILAZODONE—CLINICAL DATA</i>	91
RECENTLY APPROVED/MARKETED DRUGS.....	92
Stedesa/Zebinix (eslicarbazepine acetate)—Dainippon Sumitomo (formerly Sepracor).....	92
TABLE 80 <i>STEDESA/ZEBINIX (ESLICARBAZEPINE ACETATE)— DAINIPPON SUMITOMO (FORMERLY SEPRACOR)</i>	92
Intuniv (guanfacine)—Shire.....	93
TABLE 81 <i>INTUNIV (GUANFACINE)—SHIRE</i>	93
Treximet (Sumatriptan and Naproxen)—GSK/Pozen.....	94
TABLE 82 <i>TREXIMET (SUMATRIPTAN AND NAPROXEN)— GSK/POZEN</i>	94
Treximet ... (Continued).....	95
Pristiq (desvenlafaxine)—Pfizer/Wyeth.....	96
TABLE 83 <i>PRISTIQ (DESVENLAFAXINE)—PFIZER/WYETH</i>	96
Vimpat (lacosamide)—UCB/Schwarz Pharma	97
TABLE 84 <i>VIMPAT (LACOSAMIDE)—UCB/SCHWARZ PHARMA</i>	97
TABLE 85 <i>DEVELOPMENTAL PRODUCT FORECAST, 2009-2015 (\$ MILLIONS)</i>	98
CHAPTER EIGHT: COMPANY PROFILES	99
SUMMARY	99
TABLE 86 <i>COMPANY REVENUE AND MARKET SHARE ANALYSIS, THROUGH 2010 (\$ MILLIONS)</i>	99
TABLE 86 <i>(CONTINUED)</i>	100
TABLE 87 <i>MARKET FORECAST BY COMPANY, THROUGH 2015 (\$ MILLIONS)</i>	100
TABLE 87 <i>(CONTINUED)</i>	101
COMPANIES	101
ABBOTT LABORATORIES	101

Business Overview	101
Therapeutic Areas.....	102
<i>TABLE 88 ABBOTT LABORATORIES' LEADING PRODUCTS AND</i>	
<i>2009 REVENUE (\$ MILLIONS)</i>	<i>102</i>
Corporate Strategy	102
ALLERGAN, INC.	102
Business Overview	102
Therapeutic Areas.....	103
<i>TABLE 89 ALLERGAN'S LEADING PRODUCTS AND 2009 REVENUE</i>	
<i>(\$ MILLIONS).....</i>	<i>103</i>
Corporate Strategy	103
Business Overview	103
Therapeutic Areas.....	104
<i>TABLE 90 ASTELLAS' LEADING PRODUCTS AND 2009 REVENUE (\$</i>	
<i>MILLIONS).....</i>	<i>104</i>
Corporate Strategy	104
ASTRAZENECA	104
Business Overview	104
Therapeutic Areas.....	105
<i>TABLE 91 ASTRAZENECA'S LEADING PRODUCTS AND 2009</i>	
<i>REVENUE (\$ MILLIONS).....</i>	<i>105</i>
Corporate Strategy	105
BAYER AG	106
Business Overview	106
Therapeutic Areas.....	106
<i>TABLE 92 BAYER HEALTHCARE'S LEADING PRODUCTS AND 2009</i>	
<i>REVENUE (\$ MILLIONS).....</i>	<i>107</i>
Corporate Strategy	107
BIOGEN IDEC (FUMAPHARM AG)	107
Business Overview	107
Therapeutic Areas.....	107
<i>TABLE 93 BIOGEN'S LEADING PRODUCTS AND 2009 REVENUE (\$</i>	
<i>MILLIONS).....</i>	<i>107</i>
Corporate Strategy	108
ELI LILLY & CO.	108
Business Overview	108
Therapeutic Areas.....	108
<i>TABLE 94 ELI LILLY'S LEADING PRODUCTS AND 2009 REVENUE</i>	
<i>(\$ MILLIONS).....</i>	<i>108</i>
Corporate Strategy	109
FOREST LABORATORIES, INC.	109
Business Overview	109
Therapeutic Areas.....	110

<i>TABLE 95 FOREST LABORATORIES' LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	110
Corporate Strategy	110
GLAXOSMITHKLINE (GSK)	110
Business Overview	110
Therapeutic Areas.....	111
<i>TABLE 96 GLAXOSMITHKLINE'S LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	111
Corporate Strategy	111
JOHNSON & JOHNSON.....	112
Business Overview	112
Therapeutic Areas.....	112
<i>TABLE 97 JOHNSON & JOHNSON'S LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	112
Corporate Strategy	112
MERCCK & CO., INC.....	113
Business Overview	113
Therapeutic Areas.....	113
<i>TABLE 98 LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	114
Corporate Strategy	114
Business Overview	114
Therapeutic Areas.....	114
<i>TABLE 99 NOVARTIS' LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	115
Corporate Strategy	115
PFIZER, INC.	115
Business Overview	115
Therapeutic Areas.....	116
<i>TABLE 100 PFIZER'S LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	116
Corporate Strategy	116
SANOFI-AVENTIS.....	117
Business Overview	117
Therapeutic Areas.....	117
<i>TABLE 101 SANOFI-AVENTIS' LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	117
Corporate Strategy	117
SHIRE PHARMACEUTICALS GROUP, PLC.....	118
Business Overview	118
Therapeutic Areas.....	118
<i>TABLE 102 SHIRE'S LEADING PRODUCTS AND 2009 REVENUE (\$ MILLIONS)</i>	118
Corporate Strategy	118
Business Overview	119

Therapeutic Areas.....	119
<i>TABLE 103 TAKEDA'S LEADING PRODUCTS AND 2009 REVENUE (\$</i>	
<i>MILLIONS)</i>	<i>119</i>
Corporate Strategy	119
TEVA PHARMACEUTICAL INDUSTRIES LTD.....	120
Business Overview	120
Therapeutic Areas.....	120
<i>TABLE 104 TEVA'S LEADING PRODUCTS AND 2009 REVENUE (\$</i>	
<i>MILLIONS)</i>	<i>120</i>
Corporate Strategy	121
WATSON PHARMACEUTICALS, INC.	121
Business Overview	121
Therapeutic Areas.....	121
<i>TABLE 105 WATSON'S LEADING PRODUCTS AND 2009 REVENUE (\$</i>	
<i>MILLIONS)</i>	<i>121</i>
Corporate Strategy	121